Clinical trial NCT00704795: Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
Official title: Glucagon Responses Following Oral Glucose and Isoglycemic iv Glucose in Patients With Type 1 Diabetes - a Role for the Gastrointestinal Tract in Diabetic Hyperglucagonemia?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hyperglucagonemia
Hyperglycemia
Diabetes Mellitus
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
First posted: 2008-06-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 1 diabetes mellitus and no residual beta-cell function (C-peptide negative)

Brief summary: In order to evaluate the potential role of the gastrointestinal (GI) tract in the postprandial hyperglucagonemia, which characterizes type 1 diabetes mellitus (T1DM) (as well as type 2 diabetes mellitus (T2DM)), we wish to investigate the secretion of glucagon in patients with T1DM without residual beta-cell function during 50-g oral glucose tolerance test (OGTT) and during isoglycemic iv glucose infusion. By evaluating C-peptide negative patients with T1DM we aim to describe the glucagon response to glucose (+/-stimulation of the GI tract) independently of the potentially very important regulation of glucagon secretion by endogenous insulin secretion. A more detailed understanding of the inappropriate glucagon secretion in T1DM is highly needed in order to establish new intervention strategies in the future treatment of the growing numbers of T1DM patients.


Eligibility criteria: Inclusion Criteria:

* Caucasian over 18 years with T1DM (diagnosed according to WHO's criteria) treated with long-acting insulin
* No residual beta-cell function (arginine test without increment in plasma C-peptide - see below)
* BMI \<30 kg/m2
* Normal haemoglobin
* Informed consent

Exclusion Criteria:

* Residual beta-cell function (increment in plasma C-peptide during arginine test - see below)
* Known liver disease or affected liver enzymes (ALAT/ASAT \> 2 x upper normal limit)
* Diabetic nephropathy (se-creatinin \> 130 µM and/or albuminuria)
* Proliferative diabetic retinopathy (anamnestic)
* Treatment with medication that cannot be discontinued for 14 hours

Primary outcomes:
measure: Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.
timeFrame: months
Secondary outcomes:
measure: Responses of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) as assessed by AUC during 50-g OGTT and isoglycemic iv glucose infusion, respectively.
timeFrame: months
measure: GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.
timeFrame: Months
Other outcomes:
Locations:
city: Hellerup
country: Denmark
facility: Gentofte University Hospital
Study officials:
affiliation: University Hospital, Gentofte, Copenhagen
name: Filip K Knop, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: